More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$135788287
EPS
-2.35
P/E ratio
--
Price to sales
1.01
Dividend yield
--
Beta
1.050948
Previous close
$2.84
Today's open
$2.84
Day's range
$2.82 - $2.97
52 week range
$2.15 - $8.77
show more
CEO
Masoud Toloue
Employees
450
Headquarters
Billerica, MA
Exchange
NASDAQ Global Market
Shares outstanding
47478422
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Quanterix Announces Leadership Transition Plan
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that Everett Cunningham has stepped down as President and Chief Executive Officer and as a member of the Company's Board of Directors (the “Board”), effective immediately, to accept an opportunity in another area of the healthcare sector. The Board has appointed Jim Gute, Quanterix's Chief Commercial Officer, to serve in the addi.
Business Wire • 2 hours ago

Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology lab, to bring its LucentAD® Complete blood tests to patients across New Jersey and the surrounding area. LucentAD Complete from Quanterix is powered by the SIMOA® platform and is one of the first blood-based tests to screen for multiple biomarkers associated with Alzheimer's disease, helping p.
Business Wire • Nov 16, 2026

What Quanterix (QTRX) Said on Its Q3 Earnings Call
Quanterix NASDAQ: QTRX reported third-quarter revenue of $35 million, up 6.3% from the previous quarter but down 13.1% from a year earlier, as stronger spatial consumables sales helped the company exceed its own expectations.
MarketBeat • Nov 9, 2026

Quanterix Corporation (QTRX) Q3 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 9, 2026

Quanterix Releases Financial Results for the Third Quarter of 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the third quarter ended September 30, 2026. “We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercia.
Business Wire • Nov 9, 2026

Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to discuss its third quarter 2026 financial results. Quanterix will issue a press release regarding its third quarter 2026 financial results prior to the conference call on Monday, November 9, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.c.
Business Wire • Oct 28, 2026

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
BILLERICA, Mass. & BEIJING--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix's ultra-sensitive biomarker de.
Business Wire • Oct 7, 2026

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on the.
Business Wire • Sep 25, 2026

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the “Inducement Grants”) were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units (“RSUs”) representing 260,315 shares of Qua.
Business Wire • Sep 17, 2026

Quanterix Names Dr. Yuri Fesko Chief Medical Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company's Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix's innovative technologies and application.
Business Wire • Sep 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Quanterix Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.